Skip to Content

Ipsen SA ADR - Stock Quote IPSEY

Rating as of

Morningstar's Ipsen SA ADR Stock Analysis

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Ipsen SA ADR's Company Profile

Business Description

Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: Specialty care and Consumer Healthcare. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focus on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

65 Quai Georges Gorse, Billancourt Cedex
Boulogne, 92100, France
T +33 158335000
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings
Fiscal Year End Dec 31, 2022
Stock Type
Employees 5,744